Erythropoietin to reduce allogeneic red blood cell transfusion in patients undergoing total hip or knee arthroplasty

Vox Sanguinis

Volumn 111, Issue 3, 2016, Pages 219-225

  Voorn, V M A ^a   van der Hout, A ^a   So Osman, C ^b,c   Vliet Vlieland, T P M ^a   Nelissen, R G H H ^a   van den Akker van Marle, M E ^a   Dahan, A ^a   Marang van de Mheen, P J ^a   van Bodegom Vos, L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c GROENE HART HOSPITAL   (Netherlands)

Author keywords

allogeneic red blood cell transfusion; erythropoietin; hip arthroplasty; knee arthroplasty; meta analysis; patient blood management

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG SAFETY; EMBASE; ERYTHROCYTE TRANSFUSION; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE ARTHROPLASTY; TREATMENT INDICATION; WEB OF SCIENCE; ALLOTRANSPLANTATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; DRUG EFFECTS; ERYTHROCYTE; HIP REPLACEMENT; KNEE REPLACEMENT; METABOLISM; VENOUS THROMBOSIS;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CLINICAL TRIALS AS TOPIC; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; ERYTHROPOIETIN; HUMANS; TRANSPLANTATION, HOMOLOGOUS; VENOUS THROMBOSIS;

EID: 84977072325     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12412     Document Type: Review

References (33)

1. Goodnough LT, Maniatis A, Earnshaw P, et al.: Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106:13–22
2. Tran DHD, Wong GTC, Chee YE, et al.: Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. Expert Opin Biol Ther 2014; 14:51–61
3. Lin DM, Lin ES, Tran MH: Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev 2013; 27(4):221–234
4. Alsaleh K, Alotaibi GS, Almodaimegh HS, et al.: The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials. J Arthroplasty 2013; 28:1463–1472
5. Zhou Q, Zhou Y, Wu H, et al.: Changes of hemoglobin and hematocrit in elderly patients receiving lower joint arthroplasty without allogeneic blood transfusion. Chin Med J (Engl) 2015; 128:75–78
6. Theusinger OM, Kind SL, Seifert B, et al.: Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland. Blood Transfus 2014; 12:195–203
7. Yoshihara H, Yoneoka D: National trends in the utilization of blood transfusions in total hip and knee arthroplasty. J Arthroplasty 2014; 29:1932–1937
8. Frisch NB, Wessell NM, Charters MA, et al.: Predictors and complications of blood transfusion in total hip and knee arthroplasty. J Arthroplasty 2014; 29(9 Suppl):189–192
9. Marson BA, Shah J, Deglurkar M: Blood transfusion in hip and knee arthroplasties: the end of the pre-operative group and save? Eur J Orthop Surg Traumatol 2015; 25(5):871–875
10. Choi JK, Geller JA, Yoon RS, et al.: Comparison of total hip and knee arthroplasty cohorts and short-term outcomes from a single-center joint registry. J Arthroplasty 2012; 27:837–841
11. Sawalha S, Ralte P, Chan C, et al.: The effect of obesity on theatre utilisation time during primary hip and knee replacements. Open Orthop J 2015; 9:68–72
12. Pow RE, Vale PR: Thromboprophylaxis in patients undergoing total hip and knee arthroplasty: a review of current practices in an Australian teaching hospital. Intern Med J 2015; 45:293–299
13. Shah A, Stanworth SJ, McKechnie S: Evidence and triggers for the transfusion of blood and blood products. Anaesthesia 2015; 70(Suppl 1):10–15
14. Newman ET, Watters TS, Lewis JS, et al.: Impact of perioperative allogeneic and autologous blood transfusion on acute wound infection following total knee and total hip arthroplasty. J Bone Joint Surg Am 2014; 96:279–284
15. Friedman R, Homering M, Holberg G, et al.: Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty. J Bone Joint Surg Am 2014; 96:272–278
16. Yates AJ Jr: The relative risk of infection from transfusions after arthroplasty: commentary on articles by Richard Friedman, MD, FRCSC, et al.: “Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty” and Erik T. Newman, MD, et al.: “Impact of perioperative allogeneic and autologous blood transfusion on acute wound infection following total knee and total hip arthroplasty”. J Bone Joint Surg Am 2014; 96:e33
17. Rohde JM, Dimcheff DE, Blumberg N, et al.: Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014; 311:1317–1326
18. Higgins JPT, Green S (editors): Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. The Cochrane Collaboration, 2009
19. Canadian Orthopedic Perioperative Erythropoietin Study Group Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993; 341:1227–1232
20. Faris P: Use of recombinant human erythropoietin in the perioperative period of orthopedic surgery. Am J Med 1996; 101:28S–32S
21. de Andrade JR, Jove M, Landon G, et al.: Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthop (Belle Mead NJ) 1996; 25:533–542
22. Feagan BG, Wong CJ, Kirkley A, et al.: Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133:845–854
23. Weber E, Slappendel R, Hemon Y, et al.: Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22:249–257
24. So-Osman C, Nelissen RG, Koopman-van Gemert AW, et al.: patient blood management in elective total hip and knee-replacement surgery (part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology 2014;120(4):839–51
25. Wurnig C, Schatz K, Noske H, et al.: Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res 2001; 33:303–310
26. Na HS, Shin SY, Hwang JY, et al.: Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011; 51:118–124
27. Olijhoek G, Megens JG, Musto P, et al.: Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001; 41:957–963
28. Baarsma B, Mutsaerts M: Costs of Blood (in Dutch). ESB 2012; 97:664–666
29. Bedair H, Yang J, Dwyer MK, et al.: Preoperative erythropoietin alpha reduces postoperative transfusions in THA and TKA but may not be cost-effective. Clin Orthop Relat Res 2014; 473(2):590–596
30. Coyle D, Lee KM, Fergusson DA, et al.: Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 1999; 9:21–30
31. Davies L, Brown TJ, Haynes S, et al.: Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006; 10(44):iii-iv, ix-x, 1–210.
32. Green WS, Toy P, Bozic KJ: Cost minimization analysis of preoperative erythropoietin vs autologous and allogeneic blood donation in total joint arthroplasty. J Arthroplasty 2010; 25:93–96
33. Schipperus M.R: TRIP annual report 2012 Hemovigilance. Hemovigilance and biovigilance office the Netherlands 2012